Scinai Immunotherapeutics Ltd. (SCNI)
- Previous Close
0.4500 - Open
0.4830 - Bid --
- Ask --
- Day's Range
0.4500 - 0.4830 - 52 Week Range
0.4310 - 2.2700 - Volume
4,332 - Avg. Volume
26,417 - Market Cap (intraday)
1.992M - Beta (5Y Monthly) 2.45
- PE Ratio (TTM)
-- - EPS (TTM)
-4.4000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
www.scinai.comRecent News: SCNI
Performance Overview: SCNI
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SCNI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SCNI
Valuation Measures
Market Cap
1.99M
Enterprise Value
15.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.50
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.71%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.29M
Diluted EPS (ttm)
-4.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
6.36M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-8.7M